tildrakizumab   Click here for help

GtoPdb Ligand ID: 8093

Synonyms: Ilumetri® | Ilumya® | MK-3222 | MK3222 | SCH-900222 | SCH900222 | SUNPG1623 | tildrakizumab-asmn
Approved drug Immunopharmacology Ligand
tildrakizumab is an approved drug (EMA & FDA (2018))
Compound class: Antibody
Comment: Tildrakizumab is a monoclonal antibody directed against the p19 subunit of IL-23 (IL-23A). It exhibits efficacy in treating psoriasis [1,4]. This biologic agent may be beneficial for patients who do not tolerate current antitumour necrosis factor (TNF) therapies.
No information available.
Summary of Clinical Use Click here for help
Tildrakizumab completed Phase 3 clinical trial for plaque psoriasis (NCT01729754 and NCT01722331), and having shown significant clinical benefit over placebo and etanercept and a favourable safety profile [3], was EMA and FDA approved in 2018, for the treatment of phototherapy candidate, adult patients with moderate to severe plaque psoriasis.
Mechanism Of Action and Pharmacodynamic Effects Click here for help
Tildrakizumab binds to and neutralises the activity of IL-23, a cytokine produced by dendritic cells and macrophages and a component of both the innate and adaptive immune systems. IL-23 is a heterodimer containing IL-23A (p19) and IL-12 p40 subunits. Tildrakizumab binds to IL-23A. This action reduces IL-23-mediated activation of Th17 cells, and inhibits their release of pro-inflammatory cytokines and chemokines.
External links Click here for help